Last reviewed · How we verify
Meningococcal vaccine GSK 134612
Meningococcal vaccine GSK 134612 is a Meningococcal vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of meningococcal disease.
This vaccine stimulates the immune system to produce antibodies against meningococcal antigens, providing protection against meningococcal disease.
This vaccine stimulates the immune system to produce antibodies against meningococcal antigens, providing protection against meningococcal disease. Used for Prevention of meningococcal disease.
At a glance
| Generic name | Meningococcal vaccine GSK 134612 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GSK 134612 is a meningococcal vaccine candidate designed to induce humoral and cellular immune responses against Neisseria meningitidis. By presenting meningococcal antigens to the immune system, the vaccine trains B and T cells to recognize and eliminate the pathogen, reducing the risk of invasive meningococcal infection.
Approved indications
- Prevention of meningococcal disease
Common side effects
- Injection site pain
- Injection site erythema
- Fever
- Myalgia
Key clinical trials
- Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 (PHASE3)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers (PHASE3)
- The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers (PHASE2)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds (PHASE3)
- Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal vaccine GSK 134612 CI brief — competitive landscape report
- Meningococcal vaccine GSK 134612 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Meningococcal vaccine GSK 134612
What is Meningococcal vaccine GSK 134612?
How does Meningococcal vaccine GSK 134612 work?
What is Meningococcal vaccine GSK 134612 used for?
Who makes Meningococcal vaccine GSK 134612?
What drug class is Meningococcal vaccine GSK 134612 in?
What development phase is Meningococcal vaccine GSK 134612 in?
What are the side effects of Meningococcal vaccine GSK 134612?
Related
- Drug class: All Meningococcal vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of meningococcal disease
- Compare: Meningococcal vaccine GSK 134612 vs similar drugs
- Pricing: Meningococcal vaccine GSK 134612 cost, discount & access